# CV of Research Activities of Dr. Asghar Hajiabbasi

#### First and surname:

Asghar Hajiabbasi

#### Email:

mobasher@gums.ac.ir

#### **Education**

- o MD: School of Medicine, Guilan University of Medical Sciences, Rasht, IR Iran (1979-1988)
- o Internist: School of Medicine, Guilan University of Medical Sciences, Rasht, IR Iran (1989-1992)
- o Rheumatologist: School of Medicine, Guilan University of Medical Sciences, Rasht, IR Iran

## **Educational and Administrative Responsibilities**

- Academic Degree : Associate Professor
- Founder of Rheumatology Ward in School of Medicine, Guilan University of Medical Sciences, Rasht, IR Iran
- Head of Internal Medicine group of School of Medicine, Guilan University of Medical Sciences, Rasht,
  IR Iran
- o Founder and Head of Guilan Rheumatology Research Center (From 2011)
- o Founder of Guilan Lupus Clinic
- o Founder of Sjogren Clinic

## **Other Activities**

- Executive of Iranian Primary Sjogren Syndrome Registry
- o Executive of Guilan Branch of Iranian Systemic Sclerosis Registry
- o Steering Committee of Fibromyalgia Registry

## **Awards and Honors**

- o Leading Young Researcher
- o First Place in the Subspecialty Board Exam
- Award of Excellence in Rheumatology in School of Medicine, Guilan University of Medical Sciences, Rasht, IR Iran
- Award of Excellence in Teaching in School of Medicine, Guilan University of Medical Sciences, Rasht,
  IR Iran

## **Membership in Scientific Committees**

- o Guilan Rheumatology Research Center (President of Guilan Rheumatology Research Center)
- o Iranian Rheumatology Association
- o Iranian Primary Sjogren Syndrome Strategic and Scientific Committee
- o Iranian Systemic Sclerosis Strategic and Scientific Committee
- o Iranian Fibromyalgia Strategic and Scientific Committee

# CV of Research Activities of Dr. Asghar Hajiabbasi

### **Publications (Books in Persian)**

- 1. Arthritis Rheumatoid (editions: 1995, 2005)
- 2. Seronegative Spondyloarthropathy (edition: 1997)
- 3. Periarticular Diseases (edition: 2000)
- 4. Systemic Lupus Erythematosus (editions: 2001, 2010)
- 5. Osteoporosis (editions: 2002, 2019)
- 6. Vasculitis (editions: 2003, 2020)
- 7. Metabolic Diseases in Bones and Joints(edition: 2004) Connective Tissue Diseases (edition: 2006)
- 8. Musculoskeletal Diseases Infectious Agents (edition: 2007)
- 9. New Challenges in Rheumatology (edition: 2008)
- 10. Rheumatic Diseases in Pediatrics (edition: 2009)
- 11. Arthrosis (edition: 2010)
- 12. Complementary & Alternative Medicine in Rheumatic Diseases (edition: 2011)
- 13. Sclerodermia (edition: 2012)
- 14. Rheumatic Diseases in Pregnancy (edition: 2013)
- 15. Biologic Drugs in Rheumatology (edition: 2014)
- 16. Alternative Treatments in Rheumatology (edition: 2015)
- 17. Rehabiliation in Rheumatology (edition: 2016)
- 18. Parclinics in Rheumatology (edition: 2017)
- 19. Spondyloarthropathy (edition: 2018)
- 20. Rheumatology in elderly (edition: 2021)

## **Published Articles:**

- Ghorbanshiroudi S, Kalatbari J, Hajiabbasi A. Survey of depression and anxiety in patients with rheumatoid arthritis. Journal of Guilan University of Medical Sciences. 2013 Apr 10;22(85):15-22. (In Persain)
- 2. Mohammadi F, Zayyeni SH, Nejatifar F, Hedayati MH, Haji Abbasi A, Shenavar I, TaherKhani M. Prevalence of Musculoskeletal Disorders in the Upper Limbs of Type 2 Diabetic Patients. Journal of Guilan University of Medical Sciences. 2014 Jul 10;23(90):24-31. (In Persain)
- 3. Shafaghi A, Mansour-Ghanaei F, Rostamnejad M, Maafi AA, Haji-Abbasi A, Froutan H. Anti-cyclic citrullinated peptide antibodies in ulcerative colitis, and its relation with disease activity. Medical journal of the Islamic Republic of Iran. 2014;28:76.
- 4. Hajiabbasi A, Shafaghi A, Fayazi HS, Masooleh IS, Emami MH, Parsa PG, Maafi AA. The factors affecting bone density in cirrhosis. Hepatitis monthly. 2015 Apr;15(4).
- 5. Ghavidel-Parsa B, Bidari A, Maafi AA, Hassankhani A, Hajiabbasi A, Montazeri A, Sanaei O, Ghalehbaghi B. The impact of fibromyalgia on health status according to the types, demographic background and pain index. Clin Exp Rheumatol. 2016 Mar 1;34(2 Suppl 96):S134-9.
- 6. Masooleh IS, Hajiabbasi A, Zayeni H, Ghanbari A, Esteghamati VZ, Parsa BG, Hassankhani A. Anticyclic citrullinated peptide antibody in rheumatoid arthritis: a cross-sectional study in Iran. Turkish journal of medical sciences. 2016 Nov 17;46(5):1309-13.

# CV of Research Activities of Dr. Asghar Hajiabbasi

- 7. Zayeni H, Haji-Abbasi A, Foumani SA, Tohidi M, Masooleh IS, Parsa BG, Aghaei M, Hassankhani A, Parsa PG, Maafi AA. Pulmonary involvement in rheumatoid arthritis: A cross-sectional study in Iran. Lung India: Official Organ of Indian Chest Society. 2016 Jan;33(1):49.
- 8. Masooleh IS, Zayeni H, Haji-Abbasi A, Azarpira M, Hadian A, Hassankhani A, Parsa BG. Cardiac involvement in rheumatoid arthritis: A cross-sectional study in Iran. Indian heart journal. 2016 May 1;68(3):332-5.
- 9. Hajiabbasi A, Masooleh IS, Alizadeh Y, Banikarimi AS, Parsa PG. Secondary Sjogren's syndrome in 83 patients with rheumatoid arthritis. Acta Medica Iranica. 2016 Jul 9:448-53.
- 10. Maafi AA, Ghavidel-Parsa B, Haghdoost A, Aarabi Y, Hajiabbasi A, Masooleh IS, Zayeni H, Ghalebaghi B, Hassankhani A, Bidari A. Serum vitamin D status in Iranian fibromyalgia patients: according to the symptom severity and illness invalidation. The Korean journal of pain. 2016 Jul;29(3):172.
- 11. Jamshidi, A., Gharibdoost, F., Vojdanian, M., Soroosh, S.G., Soroush, M., Ahmadzadeh, A., Nazarinia, M.A., Mousavi, M., Karimzadeh, H., Shakibi, M.R. and Rezaieyazdi, Z.,. A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis. 2017 Arthritis research & therapy, 19(1), pp.1-9.
- 12. Ghavidel-Parsa B, Bidari A, Hajiabbasi A, Shenavar I, Ghalehbaghi B, Sanaei O. Fibromyalgia diagnostic model derived from combination of American College of Rheumatology 1990 and 2011 criteria. The Korean journal of pain. 2019 Apr;32(2):120.
- 13. Nejatifar F, Mohebbi Z, Hajiabbasi A, Mozafari R, Sotoude H. Multiple myeloma presenting with diffuse ulcers and necrotic toe. Indian Journal of Cancer. 2020 Oct 1;57(4):489.
- 14. Hajiabbasi A, Sanaei N, Zeraati P, Ghavidel-Parsa P, Halaji M. The risk of systemic lupus erythematosus associated with human Herpesvirus 8 (HHV-8) infection: A systematic review and meta-analysis. Gene Reports. 2021 Feb 25:101072.
- 15. Ala M, Mohammad Jafari R, Hajiabbasi A, Dehpour AR. Aquaporins and diseases pathogenesis: From trivial to undeniable involvements, a disease-based point of view. Journal of Cellular Physiology. 2021 Feb 8.
- 16. Jamshidi A, Gharibdoost F, Sedighi S, Hajiabbasi A, Salari AH, Khabbazi A, Mottaghi P, Tahammoli Roudsari A, Aghaei M, Shenavar Masooleh I, Sabzvari A. A Phase IV Study of the Safety and Efficacy of CinnoPar® in Iranian Patients with Osteoporosis. Journal of Osteoporosis. 2021 May 31;2021.
- 17. Jamshidi, A., Vojdanian, M., Soroush, M., Akbarian, M., Aghaei, M., Hajiabbasi, A., Mirfeizi, Z., Khabbazi, A., Alishiri, G., Haghighi, A. and Salimzadeh, A., 2022. Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial. Arthritis research & therapy, 24(1), pp.1-10.

## Scientometry at 17 November 2022

Google scholar: Total citations= 191, H Index= 7

O Scopus: Total citations= 101, H index= 5